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a  b  s t r a  c t
Elastase  plays  an  important  role  in  wound  healing process, degrading damaged tissue and  allowing com-
plete  tissue recovery.  The  levels  of human  neutrophil elastase  (HNE)  are usually controlled  by endogenous
inhibitors.  However, in the presence of high levels  of  elastase,  like the  ones  present in chronic  wounds,
the  inhibitors cannot  overcome  this  overproduction  and  the enzyme starts to degrade  the  surrounding
healthy  tissue.  In  this work  we report  the development  of a molecular  switch to  control  the  elastase
activity  in  the  exudate  of  non-healing  chronic wounds.  A  peptide  library  was generated  and screened  in a
microarray  format for protein kinase-mediated phosphorylation.  Two  peptides  were identified  as  casein
kinase  Id (CKI)  substrates:  KRCCPDTCGIKCL  and  its  analogous  peptide  KRMMPDTMGIKML, with  cysteine
residues replaced by methionine residues.  These  peptides  were  studied in  solution,  both in the phospho-
rylated and non-phosphorylated forms  as  potential  inhibitors  for  elastase. The  obtained  results show  that
the reversible process of phosphorylation/dephosphorylation  results in  differential  inhibitory activity  of
the  peptides. Thus  the reversible  process of phosphorylation/dephosphorylation  can  be  used  as  a kind  of
molecular  switch  to control  elastase activity.  Degradation  studies  reveal  that  both the  inhibitor-peptides
and CKI are  degraded by elastase.  These  results envisage  the safe  utilisation of  these inhibitor-peptides
together  with CKI in  the  formulation  of wound  dressings.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Non-healing chronic wounds, such as  pressure, venous and
diabetic ulcers, are an  important and persistent problem in der-
matology [1].  In healing acute wounds such as injuries or surgical
procedures (fluids from ablation of seborrheic warts, for exam-
ple) the levels of  protein-degrading enzymes are low whereas in
chronic non-healing wounds the exudates (from ulcers fluids, for
example) contain high levels of proteases, such as elastase and
matrix metalloproteinases (MMPs) [2–4].  Elevated levels of  elas-
tase (36–54 munits/mL wound fluid)  [5] degrade cytokine growth
factors, fibronectin and reduce the endogenous levels of  protease
Abbreviations: SLPI, secretory leukocyte protease inhibitor; ECP, eosinophil
cationic  protein; SP-D,  surfactant protein D; ESI, elastase specific inhibitor; HNE,
human neutrophil elastase; PPE, porcine pancreatic elastase; MBP, myelin basic
protein; CKId, casein kinase I  delta isoform; Ser(P), phoshoseryl residue; Thr(P),
phosphothreonyl residue; Xaa, any given aminoacid; HTS, high throughput screen;
RLUs,  relative light units; EC50 ,  enzyme concentration at 50% of  signal; Peptide
4, Pep4; Peptide 4, KRCCPDTCGIKCL; Peptide 4  Modified, Pep4M; Peptide 4 Mod-
ified,  KRMMPDTMGIKML; p-NA, p-nitroaniline; MS, mass spectrometry; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel  electrophoresis; SD, standard deviation.
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inhibitors. In  acute wounds, minimal levels of elastase (245.9 ng/mg
protein) [4] and matrix metalloproteinases (1.6 ng/mg protein
MMP-2 and 0.2  ng/mg protein MMP-13) [4] are required for an
appropriate healing process. The elastase levels are  controlled by
endogenous inhibitors such as alpha-1 proteinase inhibitor (a1-PI),
secretory leukocyte protease inhibitor (SLPI) and Elafin [6].
The levels of proteases in chronic wounds may  be reduced to lev-
els  similar to those found in  acute wounds using bioactive wound
dressings composed of  peptide [7,8] and carbohydrate derivatized
cotton  [9],  ionically derivatized dressings of  cotton [10,11] and
hydrogel polymers [12]. Controlled release of protease inhibitors
from  wound dressings and biomaterials, such as collagen, alginate,
chitosan, carboxymethylcellulose, hydrogel polymers, hydrocol-
loids and polyurethane [13,14] have also been  used to reduce
the protease burden on chronic wounds. Sequestration of elas-
tase from  the wound environment [11,12,15] or the release of
elastase inhibitors to the wound medium [5,16], are two  plau-
sible approaches to control elastase levels in wound exudates.
The present work relies on  the second concept as a methodology
to control the imbalance between proteases and their inhibitors.
The inhibitor-peptides studied herein were  selected from  the
endogenous elastase inhibitors SLPI and Elafin and from two other
endogenous proteins, eosinophil cationic protein (ECP) and surfac-
tant protein D (SP-D). Elafin and SLPI have high cysteine content,
0141-0229/$ – see front matter ©  2011 Elsevier Inc. All rights reserved.
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8  and 16 residues respectively, with the correct pairing of disul-
fide bridges being crucial for elastase inhibition [17–19].  Elafin is
a potent inhibitor of  both human neutrophil elastase (HNE) and
porcine pancreatic elastase (PPE) [18–20],  whereas SLPI is a strong
HNE inhibitor but a weak  PPE inhibitor [18–20].  SLPI  and Elafin have
multiple biological functions: anti-bacterial, anti-fungal, anti-viral,
anti-inflammatory and immune-modulatory functions [20–22].
Eosinophil cationic protein is a potent stimulator of mucus secre-
tions by airways epithelial cells [23]  acting as a host defence protein
due to its bactericidal, helminthotoxic and antiviral activities
[24–26]. Furthermore, ECP displays tissue-healing properties reg-
ulating fibroblast activity and enhancing collagen release [23,27].
Surfactant protein D (SP-D), originally described as a collagenous
glycoprotein [28],  belongs to the collectin family of  proteins, named
for their N-terminal collagen region and C-terminal lectin domain.
SP-D is a large hydrophilic molecule with host defence and immune
regulatory functions [29–31]: viral  neutralization, clearance of bac-
teria, fungi and apoptotic and necrotic cells, down regulation of
allergic reaction and resolution of inflammation [31].
Synthetic protease inhibitors are typically used for protease
inhibition. Continuous release of  (non-degradable) inhibitors from
wound dressings results, over time, in steady concentration build-
up in wounds, lowering protease activity levels below those
desirable for healing. In  vivo, the activity of  endogenous proteases
is controlled by small protein molecules (inhibitors), known as
anti-proteases. A  dynamic state of  inhibition is achieved by  regulat-
ing the relative rates of  inhibitor synthesis and protease-mediated
inhibitor degradation.
We envisage that steady-state low levels of elastase activ-
ity in chronic wounds can be achieved by sustained release of
(degradable) inhibitor-peptides from wound dressings, coupled
to elastase-mediated hydrolysis (deactivation). In addition, if the
phosphorylated form of  the inhibitor-peptides inhibit elastase to
a  less extent than the non-phosphorylated form, than protein
kinase-mediated phosphorylation reaction, can  be  seen  as  a  (0–1)
molecular switch to fine tune elastase activity.
In the current work we give the first steps towards the proof-of-
concept of this proposal: (i) a peptide  library was designed using
short peptide sequences derived from the endogenous proteins
SLPI, Elafin, ECP and SP-D; (ii) all library members contain a central
phosphorylable residue, Ser, Thr or Tyr; (iii) a  library of 49  peptide
sequences was screened in  microarray format for phosphorylable
peptides; (iv) the most robust hit identified in  the microarray assay,
Pep4, was selected for further studies; (v) the phosphorylation of
Pep4 and its analogue Pep4M with casein kinase Id (CKI) was stud-
ied in solution; (vi) the inhibition of  elastase by Pep4, Pep4M and
their phosphorylated forms was evaluated in  solution; (vii) the
degradation of Pep4, Pep4M and CKI by elastase was studied in
solution by mass spectrometry (MS) and SDS-PAGE electrophoresis,
respectively.
2. Materials and methods
2.1. Reagents
The microarrays and the peptides KRCCPDTCGIKCL (peptide 4 – Pep4) and
KRMMPDTMGIKML  (peptide 4 modified – Pep4M) were custom-made by JPT Pep-
tide Technologies GmbH (Berlin, Germany). Except where otherwise stated, all
reagents were purchased from Sigma Co  (St. Louis, MO,  USA). Casein kinase Id
(C4455), Adenosine 5′-triphosphate disodium salt (ATP, A2383) and all reagents
used to prepare the buffer solutions employed in  the microarray assays, were used
as  supplied. The microarrays chips were sealed with disposable incubation cham-
bers (AB-0630, 300 mL,  19 ×  60  mm,  frames and  coverslips, ABgene, Epsom, UK).
The blocking reagent (cat n◦11096176001) used  in the preparation of the  block-
ing buffer was acquired at Roche Diagnostics GMbH (Basel, CH). The  microarray
stain  and destain were performed using the Pro-Q diamond phosphoprotein gel
stain  (P33301) and Pro-Q diamond destain solution (P33310) from Molecular Probes
(Eugene, OR, USA).
The protein kinase assay in  solution was performed using the PKLightR High
Throughput Screen Protein Kinase assay Kit (LT07-500), from Cambrex (East Ruther-
ford, NY,  USA), in  a 96-well format (F96 NUNC, Rochester, NY, USA). This assay kit
comprises ATP detection reagent (LT27-200), reconstitution buffer A (LT27-202) and
B  (LT27-207) and  kinase stop solution (LT27-228).
Porcine pancreatic elastase (E1250), chromogenic substrate N-succinyl-Ala-Ala-
Ala-p-nitroanilide (S4760) and the non-peptide PPE inhibitor Elastatinal (BML-PI-
103, Enzo Life Sciences, Farmingdale, NY, USA) were used as supplied.
SDS-PAGE reagents: acrylamide/bisacrylamide solution (37.5:1) at 40% (161-
0148), TEMED (N,N,N′ ,N′-tetra-methyl-ethylenediamine, 161-0800) and APS
(Ammonium Persulfate, 161-0700) were purchased to Bio-Rad Laboratories (Her-
cules, CA, USA). A broad range protein marker (New England BioLabs, Ipswich, USA,
P7702S) was  used in the electrophoresis assay. All reagents used were of  analytical
grade and all aqueous solutions were prepared in  deionized water and  stored at 4 ◦C.
2.2. Methods
2.2.1. On-chip protein kinase phosphorylation
Jerini  phosphosite detector peptide arrays  (Jerini Peptide Technologies, GmbH,
Berlin, Germany) were used to identify potential phosphorylation sites within a
library of  forty-nine peptide sequences, derived from the endogenous proteins SLPI,
Elafin, ECP and SP-D. Eight controls (Histone 1, 2, 3 and 4,  myelin basic protein
(MBP), alpha- and beta-casein and  Tau  protein) were also incorporated into the
microarray format. The controls were spotted on the microarray in the four limits
of each subarray (three subarrays per array – triplicates), serving simultaneously
as positive controls and  as landmarks for  the  identification of phosphorylation sig-
nals  [32]. 13-Mers l-peptides were  generated around central serine, threonine or
tyrosine  residues in  order to improve accessibility to the  phosphor-acceptor site.
The phosphorylation on-chip was  performed according to the  PhosphoSiteDetector
Protocol, supplied by the manufacturer. Briefly: peptide arrays were sealed with
Gene-FrameTM incubation chambers (AB  0630, Abegene, Epsom, UK), the chambers
were filled with 330 mL  of  general kinase buffer (50 mM HEPES – NaOH, pH  7.5,
5  mM MgCl2 , 5 mM MnCl2 , 3 mM  Na3VO4 , 1 mM DTT  and 1 mM ATP), casein kinase
Id (10 units/mL, 8.56 mL) and ATP  (1 mM,  33 mL).  After 6 h  of  incubation at 35 ◦C,
in  a  incubator shaker (Infors HT – Minitron, Bottmingen, Switzerland), the incuba-
tion chambers were removed from the slides and the microarrays were washed five
times, for 5 min, with TBS  buffer (50 mM Tris–HCl, pH 8.0, 137  mM NaCl and 2.7 mM
KCl). Next, the chips  were incubated with the blocking solution (blocking reagent
and 100 mM maleic acid buffer, pH  7.5, 150 mM NaCl) for 1 h at 25 ◦C, rinsed  with TBS
buffer (five times for 5  min)  and then dried with airflow. The use of blocking buffer
after protein kinase incubation avoids unspecific binding of the phosphor-specific
stain, which is  applied in last  step  of  this experimental procedure.
To  detect the phosphopeptides on the microarrays (Fig. 1), a  fluorescence
phosphosensor dye – Pro-Q diamond stain (excitation/emission: 555/580 nm,
respectively) was  used. The microarrays were incubated with the stain for 60 min
and then rinsed three times with destain solution, for a  period of 30  min. This was
followed by a  final wash with ultra-pure water before drying in a nitrogen stream
and analysing in  a  microarray scanner (Agilent and QuantArray).
2.2.2. Protein kinase phosphorylation in  solution
The enzymatic activity of casein kinase Id (CKI)  was measured using the PKLightR
HTS Protein Kinase assay Kit, from Cambrex (East Rutherford, NY, USA). The protein
kinase activity measurements were performed following the  manufacturer proce-
dures. The kinase activity was  measured in  96-well, white NUNC micro-plates using
a  total volume of 20 mL per well. Casein kinase Id was serially diluted in general
kinase buffer, directly on  the  96-well microplates, to give activities ranging from
3.75  to 1.83 × 10−3 units per well. Next, a mixture of  substrate (8  mM  Pep4 or Pep4M)
and ATP (6 and 1 mM for Pep4 and Pep4M, respectively), diluted in general kinase
buffer was added to  all wells, including the  negative controls (without casein kinase
Id). The reaction mixture was incubated at 25 ◦C for 30 min, before adding 5  mL of
kinase stop solution. The amount of  ATP remaining was  determined by adding 10 mL
of ATP detection reagent to each well and incubating for 10 min  at 25 ◦C (optimal
temperature for the luciferase enzyme). The 96 well-plates were read at 560 nm on
a  BioTek, SynergyTM HT (Winooski, VT,  USA), in  luminescence mode (Fig. 2).
2.2.3. Elastase activity measurements
The activity of  porcine pancreatic elastase was assayed with the chromogenic
substrate N-succinyl-Ala-Ala-Ala-p-nitroanilide [33], in accordance with the pro-
tocol supplied by the  PPE  manufacturer. The p-nitroanilide released was analysed
in 1 mL  quartz cells and monitored by  recording the absorbance at 410 nm with
a  UV–vis Shimadzu spectrophotometer (UV-2501PC, Kyoto, Japan). Substrate con-
centration and enzyme activity of 4.4 mM and 0.3 units/mL, respectively, were used
in the assay. The enzyme was pre-incubated at 25 ◦C with the inhibitor for 5 min
before adding the substrate. The enzyme assays were conducted at 25 ◦C in 100 mM
Tris–HCl  buffer, pH 8.0. The  hydrolysis rates of  N-succinyl-(Ala)3-pNA by  PPE were
acquired in the presence of  inhibitors (Pep4, Pep4M) in  concentrations ranging from
1  to  64 mM  (Fig. 3).  The non-peptide (non-hydrolysable) inhibitor elastatinal was
used as a  control and  assayed in  the same conditions as the peptides. An assay
was also performed using the  inhibitor-peptides concentrations that decreased
mostly the elastase activity, both in  the  phosphorylated and  non-phosphorylated
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Fig. 1.  Microarray screening of  the peptide library (peptide 1–49) and protein controls (I–IV – Histone 1, 2, 3  and 4,  V – myelin basic protein (MBP), VI and VII – alpha- and
beta-casein and VIII – Tau  protein), for phosphopeptides after phosphorylation with casein kinase Id, in triplicate. The slides were probed with a  fluorescent phosphosensor
(Pro-Q  diamond phosphoprotein gel stain) and detected in  a  microarray scanner (excitation/emission: 555/580 nm,  respectively).
form  (Fig. 4). The  optimized phosphorylation conditions found for the PKLight assay
(Fig.  2) were adapted to phosphorylate the  peptides in solution. The  temperature
and incubation time  were replaced by  that used in the phosphorylation of the  pep-
tides  in the  microarray format (6  h at 35 ◦C). The  control CKI +  ATP was treated in the
same conditions as the  peptide samples.
2.2.4. Elastase degradation of inhibitor peptides Pep4 and Pep4M –  mass analysis
Mass  spectra of the  inhibitors (Pep4, Pep4M and Elastatinal) were acquired on a
Thermo Electron Corporation instrument (Waltham, MA,  USA), model Finnigan LXQ,
using electrospray ionization (ESI) in the  positive mode. Samples were prepared in
a  mixture 20% methanol/80% buffer solution. A total volume of 200 mL was directly
injected into the ionization chamber – direct introduction method. Inhibitor samples
(data not shown) and mixtures of inhibitor (0.5 mM):  elastase (0.3 units/mL), in  a
proportion 3:1 (v/v) (Table 2 and Fig. 5), were analysed after different incubation
periods  (0, 5, 15, 30, 45, 60, 90  and 120 min) at 25 ◦C.
2.2.5. Elastase degradation of  casein kinase – SDS-PAGE electrophoresis
Sodium  dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [34]
was  used to evaluate the  degradation of casein kinase Id by elastase. The SDS-PAGE
assay was  perform as described by Laemmli [34] and in  accordance to  the  Bio-Rad
Fig. 2.  Casein kinase Id titration curve using 3.75–1.83 × 10−3 units of  CK per reac-
tion  to  phosphorylate: 4  mM of  Pep4, in  the presence of  3 mM  of ATP () and 4 mM
of  Pep4M, in the presence of  0.5 mM  of  ATP ( ).  Each data point represents the
average ± SD (n = 3).
manufacturer protocols. Samples were analysed using a 4% stacking gel followed by
a  10% separating gel, under denaturing conditions. Gels were stained in Coomassie
blue  R solution (overnight) and destained with methanol/acetic acid (40%/7% and
5%/7%) solutions. Afterwards, the gels were enclosed in  sheets of cellophane mem-
brane and dried in a  gel dryer (model 563, Bio-Rad, Hercules, CA, USA) during 60  min
at 80 ◦C, under vacuum conditions.
Samples of casein kinase Id (0.1–0.4  units/mL) and elastase (0.005–0.01 units/mL)
with different concentrations were analysed by  SDS-PAGE in  order to determine
the  detection limit of the method (data  not shown). The optimal concentrations
of elastase and casein kinase Id, 0.005 and 0.2 units/mL,  respectively, were used
to prepare a  mixture of the two proteins. The reaction mixture was  incubated for
60  min. During this period several aliquots were removed (0, 5,  10, 20, 30 and  60 min)
and immediately frozen for further analysis. The thawed samples were analysed by
SDS-PAGE along with protein markers (Fig. 6).
2.2.6. Statistical analysis
Statistical analyses (standard deviation) were performed using the Microsoft
Office  Excel 2010. Prior  to  statistical treatments, data validation was  performed
using Dixon’s Q-test. A confidence level of  95% was  used as the cut off level.
3. Results and discussion
3.1. Peptide library design and on-chip phosphorylation
A peptide library was  designed using short peptide sequences
(13 mer) derived from the primary sequence of the endoge-
nous proteins SLPI, Elafin, ECP and SP-D. Phosphorylable residues,
Ser, Thr and Tyr, within the proteins primary structure were
selected as anchors and extended in  both directions with six
aminoacid residues. As such, all library members contain a cen-
tral phosphorylable residue (residue seven), Ser, Thr or Tyr,
flanked by  six amino-acid residues. For incorporation onto the
microarrays, the peptides were N-functionalized with a hydrophilic
linker, 1-amino-4,7,10-trioxa-13-tridecanamine, bearing terminal
aminooxyacetyl moieties for chemoselective immobilization onto
aldehyde-functionalized glass slides. It  is, thus, reasonable to
assume that the peptides and in  particular the central phospho-
rylable residues are accessible to enzymes. The peptide library
(Table 1)  was screened for potential substrates for protein kinases,
by means of the microarray technology. The peptide origin, its
sequence and the phosphor-aminoacids are highlighted in  Table 1.
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Fig. 3. Porcine pancreatic elastase activity assay in  the  presence of three inhibitors: Pep4 (); Pep4M ( ) and elastatinal ( ), in  concentrations ranging 1–64 mM. The
enzymatic assay was  performed using 0.3 units/mL of  PPE and 4.4 mM of  substrate, N-succinyl-Ala-Ala-Ala-p-nitroanilide, in a  100 mM Tris–HCl, pH 8.0 buffer medium. The
p-nitroanilide release was monitored in  a UV–vis spectrometer, at 410 nm.  Data  shown are the mean ±  SD of triplicate determinations.
The database NetPhos 2.0 server [35]  was  used to screen the pep-
tide library for potential phosphorylation sites (Table 1). Nineteen
peptides, out of the 49  library members, were predicted as  bearing
potential sites for phosphorylation, although only  12 displayed a
high degree of confidence score (threshold higher than 0.90).
The peptide library, immobilized on  glass slides together with
eight full-length proteins, was  initially assayed with casein kinase
Id and other protein kinases, such as protein kinase A and pro-
tein kinase C. Reliable results were obtained only  with CKI and
presented thereafter. The fluorescence intensity of each spot on
the microarray was normalized by  subtracting background’s inten-
sity. The Peptide KRCCPDTCGIKCL (entry 4 in Table 1, thereafter
Fig. 4. Porcine pancreatic elastase  (PPE) activity in the presence of  non-
phosphorylated inhibitors Pep4 ( ) and  Pep4M ( dashed), and  phosphorylated
inhibitors Pep4 Phosp ( ) and Pep4M Phosp (  dashed). Concentrations of  the Pep4
and  Pep4M inhibitors in  the assay were  1  mM  and 4 mM,  respectively. Controls in
the absence of  inhibitors PPE  () and in the presence of casein kinase Id and ATP,
CKI + ATP ( and dashed) are also shown. Two different assays are shown for the
later control corresponding to the  conditions for Pep4 phosphorylation (17.8 units
of CKI and 6 mM of  ATP) ( ) and Pep4M phosphorylation (12.6 units of CKI and 1 mM
of  ATP) ( dashed). The experimental conditions are the same as  used in Fig. 3.  The
data shown are the average of  three independent measurements.
designated Peptide 4, and abbreviated Pep4) was  the only pep-
tide found to be reproducibly phosphorylated by CKI in the three
sub-arrays. Peptide GKCPVTYGQCLML (entry 9), RCPHNRTLNNCHR
(entry 25) and GESLVYSNWAPGE (entry 37) and the protein
controls Histone I,  Histone II and a-Casein, were also phos-
phorylated although not reproducibly in the three sub-arrays.
Interestingly, out of the 4  hits only peptide GESLVYSNWAPGE
(entry 37) was predicted by NetPhos 2.0 as a  potential substrate for
phosphorylation. Peptide KRCCPDTCGIKCL (Pep4), the most reliable
hit found, was  not identified by the NetPhos server as a potential
substrate for protein kinases. Accessibility to  the phospho-site or
different conformations on the immobilized state might explain
the discrepancies observed. Casein kinase I belongs to a  fam-
ily of Ser/Thr protein kinases, characterized by  its  preference for
acidic protein substrates, such as  casein and phosvitin, containing
acidic residues (Glu or Asp) in the vicinity of  the phosphoryla-
tion  sites [36]. Prior substrate phosphorylation was  identified as
critical for CKI phosphorylation [37]. A  consensus sequence with
Fig. 5. MS study on the  degradation of the inhibitors Pep4 ( ),  Pep4M ()  and Elas-
tatinal ( ) (0.5 mM)  by PPE (0.3 units/mL), in  a  ratio 3:1 (v/v), during an incubation
period of  120 min. Data  points represent the  mean of  three assays ± SD.
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Fig. 6. Electrophoresis (SDS-PAGE) study on the degradation of  casein kinase Id
(0.2  units/mL) by PPE (0.005 units/mL),  in  a  ratio 40:1 (v/v). The SDS-PAGE gel was
revelled in Coomassie Blue. Lane 1: Markers; lane 2:  0.2 units/mL of  casein kinase Id
(41.8  kDa); lane 3: 0.005 units/mL of  elastase (29.9 kDa) and  lanes 4–9: mixture of
elastase and casein kinase Id in  a proportion 1:40.
N-terminal pre-phosphorylated residues, Ser(P)/Thr(P)-Xaa-Xaa-
Ser/Thr (Xaa – any aminoacid), is not an absolute requirement
for efficient and high-affinity phosphorylation by CKI as long as
multiple acidic residues are present on the N-terminal side of the
phosphor-acceptor aminoacid. Such behaviour supports the con-
cept that CKI could act as  a primary protein kinase [37] and not only
as a secondary protein kinase (requiring previous substrate phos-
phorylation) [38].  Nonetheless, phosphoserine/phosphothreonine
determinants are superior to carboxylic amino acids, as specific
determinants for CKI [38].  Despite not containing the consensus
sequence, the acidic aspartic acid residue (D) on the N-terminal
side of the phosphor-acceptor residue rends Pep4 an  appropriate
substrate for CKI. In this assay, casein kinase Id behaves as a  primary
protein kinase [37].
3.2. Phosphorylation of the  inhibitor peptides in solution
The most reliable hit identified in the microarray assay as
substrate for casein kinase Id,  Pep4 (KRCCPDTCGIKCL), was pur-
chased from JPT Technologies. An  analogous peptide, in which
the 4  cysteine residues were replaced by methionine residues
(KRMMPDTMGIKML), thereafter designated Pep4M, was also pur-
chased. This peptide was used as  control to exclude aggregation
or some other form of oligomerization of  Pep4 in solution, result-
ing from intramolecular and/or intermolecular disulfide bridges.
The CKI-mediated phosphorylation of both peptides  in  solution was
assessed using the PKLight HTS in vitro assay (Fig. 2) [39].  Different
concentrations of  peptide (4 and 8 mM) and ATP (1, 2,  6 or 8 mM) and
incubation periods (15,  30 or 50  min) were tested for optimizing
phosphorylation reactions (data not shown). The best results were
obtained with 30 min  of  incubation with CKI, 8  mM  concentration
of both peptides, together with 6 and 1 mM concentration of ATP for
Pep4 and Pep4M, respectively. This assay validates the microarray
result confirming that Pep4 is a substrate for CKI-mediated phos-
phorylation. Mutated (cysteine → methionine) peptide Pep4M, is
also a substrate for CKI.  The values of EC50 (the  concentration of
enzyme that gives 50% of maximum peptide phosphorylation [40])
were determined from CKI titration curves using 7.94 and 3.16 units
of casein kinase Id,  for Pep4 and Pep4M, respectively.
3.3. Elastase activity measurements
The inhibition of porcine pancreatic elastase by peptides Pep4
and Pep4M was  assayed in vitro with the chromogenic substrate N-
succinyl-Ala3-pNA (Fig. 5). Elastatinal, a non-peptide low molecular
weight (aldehyde) [41],  was  used as a  specific inhibitor of elas-
tase for control purposes. For elastatinal, a  positive correlation was
established between its concentration and the inhibition of  PPE.
For the inhibitors Pep4 and Pep4M a  positive correlation could not
be unambiguously established in  the range of  concentrations stud-
ied. The highest level of  inhibition, circa 40%, was  achieved with
1 mM and 4  mM  concentrations of  Pep4 and Pep4M, respectively.
At  1 mM concentration Pep4 is significantly more  potent than elas-
tatinal. At 4 mM concentration both Pep4 and Pep4M are as  potent
as elastatinal. The moderate level of inhibition achieved with both
peptides suits the objective of the current study. In fact, “complete”
inhibition of elastase in wound medium is not required or even
recommended. The use of inhibitors aims at restoring the elastase
levels, typically found in chronic wounds (2480.0 ng/mg protein),
to levels similar to those representative of  acute healing wounds
(245.9 ng/mg protein) [2,4,15].
Phosphorylated cotton wound dressings have been used to
sequester excessive protease levels in  non-healing chronic wounds,
lowering elastase and collagenase activity 40–80%, respectively,
comparing to untreated cotton dressings [10,11].  The effect of  phos-
phorylation on elastase inhibition was  studied for peptides Pep4
and Pep4M. We  envisage that a significant difference in  inhibi-
tion potency between the phosphorylated and non-phosphorylated
forms  of the inhibitors could be used for tuning elastase activity in
the  wound environment. In fact, phosphorylated peptides Pep4  and
Pep4M at 1 and 4 mM concentrations, respectively, are significantly
weaker inhibitors than their non-phosphorylated forms (Fig. 4). To
exclude the possibility that the decrease observed on  elastase inhi-
bition with the phosphorylated peptides could result from some
interaction between elastase and CKI/ATP, as  the phosphoryla-
tion reagents are not separated from the phosphorylated peptides
prior testing, elastase activity was measured in the presence of
CKI/ATP at the same concentrations as used in the phosphoryla-
tion assays. As can be seen (Fig. 4), the elastase activity is virtually
unaffected by the phosphorylation reagents. These results empha-
size that the decrease of  elastase inhibition levels obtained with
the phosphorylated peptides, is in  fact due to phosphorylation.
Phosphorylation of  the inhibitor-peptides turns-off their activity.
Phosphatase-mediated dephosphorylation could conceivably turn-
on (restore) their activity.
Thus, the phosphorylation/dephosphorylation process of
inhibitor peptides can be conceived as a “kind of”  on-off molecular
switch, to fine tune the elastase activity in  chronic wounds
3.4. Peptide degradation studies – by mass spectrometry
In normal wound healing the regeneration of  skin tissues is
performed by keratinocytes and fibroblasts. Fibroblasts play a  cru-
cial role in mediating wound healing responses, ranging from the
remodelling of the extracellular matrix (ECM) to the production of
grow factors [42].  Degrading processes, like destruction of  extracel-
lular  matrix and grow factors, prevent wound closure. Therefore,
the active materials (inhibitors, moisturiser, antimicrobial, among
others) to be delivered by wound dressings to the wound environ-
ment, have to be degraded by the wound medium, otherwise they
can act as  harmful contaminants and compromise other biological
processes relevant to wound healing. Hence, degradation studies
of the inhibitor peptides and casein kinase Id by elastase, were per-
formed in  vitro. The ESI mass spectra of Pep4, Pep4M and Elastatinal
(data  not shown) display main peaks at m/z 1439.92, 1552.06 and
555.6, respectively, in accordance to  calculated molecular weights.
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Table 1
Peptide library identification and putative phosphorylation sites for the selected peptides. Peptide phosphorylation site predictions were performed at NetPhos 2.0 server.
Peptide
number
Origin Protein primary structure Protein
fragment
Sequence (N → C) Targeted
kinase type
Reacted kinase NetPhos predictiona NetPhos
score
1 SLPI SGKSFKAGVC PPKKSAQCLR
YKKPECQSDW QCPGKKRCCP
DTCGIKCLDP VDTPNPTRRK
PGKCPVTYGQ CLMLNPPNFC
EMDGQCKRDL KCCMGMCGKS
CVSPVKA
9–21 VCPPKKSAQCLRY S Casein kinase Id –  –
2 ′′ 22–34 KKPECQSDWQCPG S ′′ –  –
3 ′′ 94–106 MGMCGKSCVSPVK S ′′ MGMCGKSCVSPVK 0.680
4 ′′ 36–48 KRCCPDTCGIKCL T ′′ –  –
5 ′′ 47–59 CLDPVDTPNPTRR T ′′ CLDPVDTPNPTRR 0.991
6 ′′ 51–63 VDTPNPTRRKPGK T ′′ VDTPNPTRRKPGK 0.968
7 ′′ 61–73 PGKCPVTYGQCLM T ′′ –  –
8 ′′ 15–27 SAQCLRYKKPECQ S ′′ –  –
9 ′′ 62–74 GKCPVTYGQCLML T ′′ –  –
10  R-Elafin AQEPVKGPVS TKPGSCPIIL
IRCAMLNPPN RCLKDTDCPG
IKKCCEGSCG MACFVPQ
4–16 PVKGPVSTKPGSC S/T ′′ PVKGPVSTKPGSC 0.991
11 ′′ 9–21  VSTKPGSCPIILI S/T ′′ –  –
12 ′′ 42–54 KKCCEGSCGMACF S ′′ –  –
13 ′′ 5–17 VKGPVSTKPGSCP S/T ′′ VKGPVSTKPGSCP 0.991
14 ′′ 30–42 NRCLKDTDCPGIK T ′′ –  –
15 ECP MRPPQFTRAQ WFAIQHISLN
PPRCTIAMRA INNYRWRCKN
QNTFLRTTFA NVVNVCGNQS
IRCPHNRTLN NCHRSRFRVP
LLHCDLINPG AQNISNCRYA
DRPGRRFYVV ACDNRDPRDS
PRYPVVPVHL DTTI
12–24 FAIQHISLNPPRC S ′′ –  –
16 ′′ 54–66 NVCGNQSIRCPHN S ′′ –  –
17 ′′ 69–81 LNNCHRSRFRVPL S ′′ –  –
18 ′′ 89–101 PGAQNISNCRYAD S ′′ PGAQNISNCRYAD 0.926
19 ′′ 114–126 NRDPRDSPRYPVV S ′′ NRDPRDSPRYPVV 0.998
20 ′′ 1–13  MRPPQFTRAQWFA T ′′ –  –
21 ′′ 19–31 LNPPRCTIAMRAI T ′′ LNPPRCTIAMRAI 0.643
22 ′′ 37–49 RCKNQNTFLRTTF T ′′ –  –
23 ′′ 41–53 QNTFLRTTFANVV T ′′ –  –
24 ′′ 42–54 NTFLRTTFANVVN T ′′ –  –
25 ′′ 62–74 RCPHNRTLNNCHR T ′′ –  –
26 ′′ 28–40 MRAINNYRWRCKN – ′′ –  –
27 ′′ 93–105 NISNCRYADRPGR S ′′ NISNCRYADRPGR 0.958
28 ′′ 102–114 RPGRRFYVVACDN – ′′ –  –
29 ′′ 117–129 PRDSPRYPVVPVH S ′′ PRDSPRYPVVPVH 0.988/0.884
30 SP-D ASLRQQVEAL QGQVQHLQAA
FSQYKKVELF PNGQSVGEKI
FKTAGFVKPF TEAQLLCTQA
GGQLASPRSA AENAALQQLV
VAKNEAAFLS MTDSKTEGKF
TYPTGESLVY SNWAPGEPND
DGGSEDCVEI FTNGKWNDRA
CGEKRLVVCE F
16–28 HLQAAFSQYKKVE S ′′ –  –
31 ′′ 29–41 LFPNGQSVGEKIF S ′′ –  –
32 ′′ 60–72 AGGQLASPRSAAE S ′′ AGGQLASPRSAAE 0.885
33 ′′ 63–75 QLASPRSAAENAA S ′′ QLASPRSAAENAA 0.835
34 ′′ 84–96 NEAAFLSMTDSKT S/T ′′ NEAAFLSMTDSKT 0.974
35 ′′ 88–100 FLSMTDSKTEGKF S/T ′′ FLSMTDSKTEGKF 0.966
36 ′′ 101–113 TYPTGESLVYSNW S/T ′′ –  –
37 ′′ 105–117 GESLVYSNWAPGE S ′′ GESLVYSNWAPGE 0.771
38 ′′ 118–130 PNDDGGSEDCVEI S ′′ –  –
39 ′′ 37–49 GEKIFKTAGFVKP T ′′ –  –
40 ′′ 45–57 GFVKPFTEAQLLC T ′′ –  –
41 ′′ 52–64 EAQLLCTQAGGQL T ′′ –  –
42 ′′ 86–98 AAFLSMTDSKTEG S/T ′′ AAFLSMTDSKTEG 0.924/0.872
43 ′′ 90–102 SMTDSKTEGKFTY S/T ′′ SMTDSKTEGKFTY 0.516/0.971
44 ′′ 95–107 KTEGKFTYPTGES S/T ′′ –  –
45 ′′ 98–110 GKFTYPTGESLVY S/T ′′ –  –
46 ′′ 126–138 DCVEIFTNGKWND T ′′ –  –
47 ′′ 18–30 QAAFSQYKKVELF S ′′ QAAFSQYKKVELF 0.561
48 ′′ 96–108 TEGKFTYPTGESL S ′′ –  –
49 ′′ 104–116 TGESLVYSNWAPG S/T ′′ TGESLVYSNWAPG 0.771
a The NetPhos 2.0 server [35]  produces neural network predictions for serine, threonine and tyrosine phosphorylation sites in  eukaryotic proteins. The prediction method
can be accessed at  http://www.cbs.dtu.dk/services/NetPhos/.  The current phosphorylation sites predictions were  acquired for  a threshold above 0.5 (higher score 1.0).
The degradation of inhibitor peptides Pep4, Pep4M and Elastatinal
(0.5 mM)  by elastase (0.3 units/mL) in  a  ratio 3:1 (v/v) was  studied
by MS  spectrometry over  120 min  (Table 2  and Fig. 5).  In the elas-
tatinal assay, no decrease of the peak at m/z  555.6 was  observed,
confirming that this non-peptide inhibitor is  not  degraded by elas-
tase during the incubation period of  the assay.
The decrease of the area of the peaks at m/z 1439.92 and 1552.06,
corresponding to intact peptides Pep4 and Pep4M, respectively,
suggests enzymatic degradation. It can be concluded that both
peptides are degraded by elastase, with Pep4 being much more
susceptible to proteolysis than  Pep4M. After 60 min of  incubation
approximately 93% of Pep4 had been degraded comparing to only
6% of Pep4M. It is consensually accepted that PPE cleaves peptides
predominantly at the C-terminal of hydrophobic amino acids such
as Gly, Val, Leu, Ala, Ile, and to lesser extent after Phe, Pro, Glu,
and Arg  [43,44].  The disappearance of  peptides Pep4 and Pep4M
correlates with the appearance of  fragments at m/z 923.66 and
1179.89, respectively, putatively assigned to fragments KRCCPDTC
Table 2
MS study on the degradation of  Pep4, Pep4M and Elastatinal (0.5  mM) by  PPElastase (0.3 units/mL), in a  ratio  3:1  (v/v) during an incubation period of 120  min.
Inhibitor Structure  Incubation period (min)
5 15 30 45 60 90  120
Relative abundance ± SD (%)
Pep4 KRCCPDTCGIKCL 100  ± 0 82.1 ± 5.1 24.3 ± 7.3 13.2 ±  3.4 7.3 ± 2.9  0.9  ±  1.6 0
Pep4M KRMMPDTMGIKML 100  ± 0 100 ± 0 100 ± 0  100 ±  0 93.6 ± 3.4  38.6  ±  8.3 0
Elastatinal C21H36N8O7 100  ± 0 100 ± 0 100 ± 0  100 ±  0 100 ± 0  100 ±  0  100 ± 0
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and KRMMPDTMGI. This is in  accordance to a new study that has
identified Ala, Val, Ile,  Thr, Ser, Leu, and Met  as potential cleavage
sites for PPElastase [45].  These results might also explain the data
obtained for elastase inhibition by these peptides. The degradation
of the peptides by elastase means that they are not true inhibitors of
the enzyme. They are actually substrates with a slow rate of  hydrol-
ysis. Consequently, at low peptide concentrations their hydrolysis
rate is very low and therefore they  function as inhibitors. How-
ever, at higher concentrations the hydrolysis rate increases and
their inhibitory effect is decreased.
It is  worth noting that the degradation studies in  vitro were
performed using elastase at higher concentration, 75 munits/mL
(1 part PPE (0.3 units/mL):3 parts inhibitor), than that present in
wound medium, 36–54 munits/ml [5]. It is, thus, reasonable to
assume that the inhibitor peptides might display longer life  times
in wound exudates, suitable for practical applications in wound
dressings. In conclusion, both inhibitor-peptides are degraded by
elastase and can be assumed safe for applications as active materials
in wound dressings.
3.5. Casein kinase degradation studies – by mass SDS-PAGE
Degradation studies of casein kinase Id by elastase were per-
formed by SDS-PAGE. Preliminar studies were performed in order
to determine the  detection limit for CKI and elastase in SDS-PAGE
and the optimal assay conditions (data not shown). A mixture of
elastase (0.005 units/mL) and CKI (0.2 units/mL),  was incubated for
60 min  at 37 ◦C.  Aliquots were removed from  the reaction mixture
at different incubation periods and analysed by SDS-PAGE (Fig. 6).
After 10 min  the bands corresponding to CKI are not detectable indi-
cating that CKI has been degraded to a  level below its detection
limit. In contrast, the elastase bands can still be seen even after
60 min  of  incubation. The elastase-mediated degradation of  CKI,
as pointed out above for the inhibitor-peptides, indicates that CKI
might be safely used also in the formulation of wound dressings.
4. Conclusions
In the present study, a  library of 13 mer peptides, derived from
the primary sequence of the endogenous proteins SLPI, Elafin,
ECP and SP-D, was designed. The central position (position 7) of
each library member was chosen bearing a phosphor acceptor site.
Screening the library in  a  microarray format  identified a robust hit,
Pep4, which could be reliably phosphorylated by CKI.  This pep-
tide was  characterised in solution as  a moderate PPE inhibitor.
Replacement of  the four cysteine residues on Pep4 by methionine
residues generated a new  peptide (Pep4M), also a  good substrate
for CKI and a  moderate inhibitor of  PPE. Both phosphorylated
peptides demonstrated to be weaker inhibitors of  PPE than their
dephosphorylated forms. MS  and SDS-PAGE studies demonstrated
that both peptides and CKI are  degraded by elastase. The use  of
inhibitors that are  degraded by their target enzyme is  desirable
for safe application in  wound dressings. The controlled release
of inhibitor-peptides coupled to degradation by the target pro-
tease can be seen as a biomimetic safe approach for controlling
protease burden in chronic wounds. Moreover, differential inhi-
bition by the phosphorylated and dephosphorylated forms of the
peptides could allow fine tuning the elastase inhibition process.
It is important to stress that this is a  model system, intended
as proof-of-concept. In this context, CKI was selected as  a  model
(available) enzyme, not present, as far  as we know, on wound exu-
dates. Our research group has described recently elastase-mediated
controlled-release of  inhibitor peptides from degradable biomatri-
ces composed of  silk fibroin and keratin [46,47].  This system could
conceptually be extended to combine a first layer containing the
inhibitor-peptide and a second layer containing the protein kinase.
Practical implementation of the concept devised in this study will
require deep knowledge about the composition of  wound exudates
and extensive optimisation of biomatrices, inhibitor-peptides and
kinase degradation rates and loadings.
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